Reaferon - instructions for use, reviews, analogs and forms of release (Lipint capsules, injections in EU ampoules, suspension of the EU Lipint) drugs for the treatment of herpes, hepatitis and other viral diseases in adults, children and pregnancy

In this article, you can read the instructions for using the drug Reaferon. Comments of visitors of the site - consumers of this medication, as well as opinions of doctors specialists on the use of Reaferon in their practice are presented. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Reaferon in the presence of existing structural analogs.Use to treat herpes, hepatitis and other viral diseases and neoplasms in adults, children, as well as during pregnancy and lactation.

Reaferon - interferon. It is a highly purified sterile protein containing 165 amino acids. Identical to human leukocyte Interferon alpha-2a. Has antiviral, antitumor and immunomodulating activity. It is possible that the mechanism of antiviral and antitumor activity is associated with a change in the synthesis of RNA, DNA and proteins. Inhibits the replication of viruses in virus-infected cells. Increases the phagocytic activity of macrophages and enhances the specific cytotoxic effect of lymphocytes on target cells.

Reaferon EU Lipint is an antiviral and immunomodulatory drug, it is an interferon alpha 2b human recombinant, encapsulated in liposomes and lyophilized dried.

Composition

Interferon alfa-2a + excipients (EU Reaferon).

Interferon alfa-2b + excipients (Reaferon Lipint).

Interferon alfa-2b human recombinant + auxiliary substances (Reaferon EU Lipint).

Pharmacokinetics

After intramuscular injection, the maximum concentration of interferon alfa-2a is noted after 3.8 hours. After subcutaneous administration, the maximum concentration is reached after 7.3 h. After intravenous administration, Vd after intravenous administration is 0.4 l / kg on an average. Interferon alfa-2a undergoes rapid metabolism in the kidneys and, to a lesser extent, in the liver. It is excreted mainly by the kidneys.

Indications

Neoplasms of the lymphatic system and hematopoiesis system:

• hairy cell leukemia;
• myeloma;
• cutaneous T-cell lymphoma;
• chronic myelogenous leukemia;
• thrombocytosis in myeloproliferative diseases;
• non-Hodgkin's lymphoma of a low degree of malignancy.

Solid tumors:

• Kaposi's sarcoma in patients with AIDS without opportunistic infections in the anamnesis;
• advanced renal cell carcinoma;
• melanoma with metastases;
• melanoma after surgical resection (tumor thickness more than 1.5 mm) in the absence of lesion of lymph nodes and distant metastases.

Viral diseases:

• chronic active hepatitis B in adults with viral replication markers (positive for HBV DNA, DNA polymerase, HBeAg);
• chronic active hepatitis C in adults with antibodies to hepatitis C virus or HCV RNA in the serum and increased ALT activity without signs of hepatic decompensation (Child-Pugh class A);
• genital warts;
• diseases caused by viruses Herpes simplex type 1 and 2 and Varicella zoster (including simple and herpes zoster, recurrent herpes of the face, genitalia, herpetic gingivitis and stomatitis);
• prevention and treatment of influenza and ARI in adults and children;
• Tick-borne encephalitis.

Atopic diseases, allergic rhinoconjunctivitis, bronchial asthma during specific immunotherapy.

Urogenital chlamydial infection in adults.

Forms of release

Lyophilized powder for solution for injection and topical application 0.5, 1, 3 and 5 million IU (EU Reaferon) (injections in ampoules for injections).

Capsules 500 000 IU (Reaferon Lipint).

Lyophilizate for the preparation of a suspension for oral administration of 250 thousand and 500 thousand IU (Reaferon EU Lipint).

Other dosage forms, whether candles or tablets, are not registered at the time of drug description in the reference book.

Instructions for use and dosing regimen

Injections Reaferon EU

Intramuscularly (in the hearth or under the lesion), subconjunctival, local. Acute hepatitis B - 1 million IU intramuscularly 2 times a day for 5-6 days (course - 15 million IU); chronic active hepatitis B - 1 million IU IM / m 2 times a week for 1-2 months; chronic active hepatitis B and D (with signs of cirrhosis of the liver) - 250-500 thousand IU per day v / m 2 times a week for 1 month; hairy cell leukemia - 3-6 million IU daily for 2 months, (course - 420-600 million IU); kidney cancer - 3 million IU daily for 10 days (course - 120-300 million IU); stromal keratitis and keratoiridocyclitis - subconjunctival for 60 thousand IU in a volume of 0.5 ml daily (course - 15-25 injections).

Capsules Reaferon Lipint

The drug is taken orally, 30 minutes before meals.

When treating influenza and ARVI: 500 000 IU (1 capsule) daily 2 times a day for 5 days.

For the prevention of influenza and SARS: 500 000 IU (1 capsule) per day, 2 times a week for a month.

If swallowing is difficult, capsules are carefully opened and the contents taken with a small amount of water.

Suspension Reaferon EU Lipint

The drug is intended for oral administration. Immediately before use, 1-2 ml of distilled or cooled boiled water is added to the contents of the vial.When shaking for 1 to 5 minutes, a uniform suspension should form.

In acute hepatitis B, the drug is taken 30 minutes before meals according to the following scheme: adults and children of school age are prescribed 1 million ME 2 times a day for 10 days; children of preschool age (from 3 to 7 years) - 500 thousand ME once a day for 10 days or after control biochemical blood tests for a longer time (until complete clinical recovery).

In chronic hepatitis B in active and inactive replicative forms, as well as in chronic hepatitis B associated with glomerulonephritis, the drug is taken 30 minutes before meals as follows: adults and children of school age are prescribed 1 million ME 2 times a day for 10 days and then switch to the administration 1 time per night every other day for 1 month; children of preschool age (from 3 to 7 years) - 500 thousand ME 2 times a day for 10 days and then switch to the introduction of 500 thousand ME once a night every other day for 1 month.

When carrying out specific immunotherapy, the drug is taken in the morning, 30 minutes after eating, according to the following scheme: for adults with allergic rhinoconjunctivitis, 500,000 IU are given to adults every day for 10 days (the course dose is 5 million.ME); Atopic bronchial asthma adults - 500 thousand ME once a day for 10 days, and then 500 thousand ME every other day for 20 days. The total duration of treatment is 30 days.

For the prevention of influenza and acute respiratory disease, the drug is taken 30 minutes before meals; adults and children over 15 years of age are prescribed 500,000 ME twice a week for 1 month during the rise in the incidence rate; children from 3 to 15 years - 250 thousand ME 2 times a week for 1 month during the rise in the incidence. When treating influenza and acute respiratory infections, adults and children over 15 years of age - 500,000 ME each 2 times a day for 3 days; children from 3 to 15 years - 250 thousand ME 2 times a day for 3 days.

In the complex therapy of urogenital infections, adults are prescribed 500,000 IU twice a day for 10 days.

Side effect

• lethargy;
• fever;
• chills;
• muscle pain;
• headache;
• pain in the joints;
• increased sweating;
• dizziness;
• impaired vision;
• depression;
• confusion of consciousness;
• nervousness;
• anxiety;
• sleep disorders;
• tremor;
• severe drowsiness;
• convulsions;
• disorders of cerebral circulation;
• ischemic retinopathy;
• loss of appetite;
• nausea, vomiting;
• diarrhea;
• decrease in body weight;
• flatulence;
• heartburn;
• relapses of peptic ulcer and bleeding from the gastrointestinal tract;
• changes in blood pressure;
• edema;
• cyanosis;
• arrhythmias;
• a feeling of palpitations;
• pain in the chest;
• slight shortness of breath;
• cough;
• pulmonary edema;
• symptoms of chronic heart failure;
• sudden cardiac arrest;
• myocardial infarction;
• increased levels of urea, creatinine and uric acid in the blood plasma;
• thrombocytopenia, decreased hemoglobin and hematocrit;
• rash;
• itching;
• alopecia;
• dry skin and mucous membranes;
• rhinitis;
• nose bleed;
• individual intolerance to interferon preparations.

Contraindications

• severe heart disease (including in history);
• severe renal dysfunction;
• severe violations of liver function;
• severe disorders of the myeloid germ of hematopoiesis;
• seizures and / or dysfunction of the central nervous system;
• chronic hepatitis with severe decompensation or with cirrhosis of the liver;
• chronic hepatitis in patients receiving or recently received therapy with immunosuppressants (except for short-term treatment with steroids);
• patients with chronic myelogenous leukemia (if the patient has an HLA-identical relative, and he will or may have an allogeneic bone marrow transplant in the near future);
• hypersensitivity to recombinant interferon alpha-2a;
• severe allergic diseases;
• pregnancy.

Application in pregnancy and lactation

The drug is contraindicated in pregnancy.

It is not known whether interferon alpha 2b is excreted in breast milk. If it is necessary to use during the lactation period, the question of stopping breastfeeding should be solved.

Women of childbearing age in the period of treatment should use reliable contraception.

special instructions

Joint use with drugs, oppressive CNS, immunosuppressive drugs (including glucocorticosteroids (GCS) for systemic use) should be avoided.

During the use of the drug, alcohol consumption is not recommended.

Use with caution in patients with impaired renal, hepatic, and bone marrow hematopoiesis, with a tendency to suicidal attempts.

Patients with diseases of the cardiovascular system may have arrhythmia. If the arrhythmia does not decrease or increases, the dose should be reduced 2 times, or stop treatment.

During the period of treatment, control of the neurological and mental status is necessary.

With severe oppression of bone marrow hematopoiesis, a regular study of the composition of peripheral blood is necessary.

Impact on the ability to drive vehicles and manage mechanisms

Depending on the dosage regimen and the individual sensitivity of the patient interferon alfa-2a may influence the reaction rate, the ability to potentially hazardous activities including driving vehicles, working with machines and mechanisms.

Drug Interactions

Interferon alpha-2b is able to reduce the activity of cytochrome P450 isoenzymes and therefore while applying affect the metabolism of cimetidine, phenytoin dipyridamole, theophylline, diazepam, propranolol, warfarin, some cytostatics.

The drug may exacerbate neurotoxic, myelotoxic or cardiotoxic action of drugs prescribed previously or simultaneously therewith.

Analogues of the drug Reaferon

Structural analogs for the active substance:

• Altevir;
• Alfaron;
• Viferon;
• Grippferon;
• Interferon alfa-2b is a human recombinant;
• Inter;
• Interferal;
• Intron A;
• Infagel;
• Layfferon;
• EU Reaferon;
• Reaferon EU Lipint;
• Reaferon Lipint;
• Roferon A;
• Eberon alpha R.

Similar medicines:

Other medicines: